HB2267

In school health services, providing for possession and use of prescribed pancreatic enzyme replacement therapy.

Introduced·3/9/26
Introduced Text

Pennsylvania HB2267 allows secondary school students with pancreatic insufficiency or cystic fibrosis to possess and self-administer prescribed.

Pennsylvania HB2267 amends the Public School Code of 1949 to allow secondary school students with pancreatic insufficiency or cystic fibrosis to possess and self-administer prescribed pancreatic enzyme replacement therapy in school. The bill requires parents or guardians to provide a signed order from a health care practitioner, a written request, and acknowledgments from the school nurse and student. The school entity must adopt a policy allowing possession and self-administration of the therapy, ensuring it is stored in a readily accessible place if not self-carried by the student.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Education Committee
Next
Committee decision

Sponsors

DDDDDDDDDDDDDD
14
6
RRRRRR
Democratic CaucusRepublican Caucus

History

Mar 9

House

Referred to Education